NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Frequently asked questions
What sector does Neuraxis, Inc. (NRXS) operate in?
Neuraxis, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Neuraxis, Inc. (NRXS) current stock price?
As of the latest data, Neuraxis, Inc. stock price is $7.25, with a previous close of $7.40. Neuraxis, Inc. lost -$0.15 in the last trading session, representing a -2.03% loss.
What is Neuraxis, Inc. (NRXS) current market capitalization?
Neuraxis, Inc. market cap is approximately 91.04 million.
What is Neuraxis, Inc. (NRXS) Earnings Per Share (EPS)?
The trailing EPS is -$0.76, and the forward EPS is -$0.27.
What is Neuraxis, Inc. (NRXS) EBITDA?
Neuraxis, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.05 million.
Does Neuraxis, Inc. (NRXS) pay dividends?
No. Neuraxis, Inc. does not pay a dividend.
How did Neuraxis, Inc. (NRXS) perform in its most recent earnings report?
In the last report (June 30, 2026), Neuraxis, Inc. posted an EPS surprise of 40.63% and a revenue surprise of -3.57%.
What is Neuraxis, Inc. (NRXS) beta (volatility) score?
Neuraxis, Inc. has a beta of 1.453, suggesting it is more volatile than the market.
